CervoMed Refines DLB Drug, Eyes Pivotal Phase 3 Trial

BOSTON, MA – March 04, 2026 – CervoMed Inc. today announced a critical step forward for its lead drug candidate, neflamapimod, setting a clear course for a planned Phase 3 trial in patients with Dementia with Lewy Bodies (DLB), a devastating neurodegenerative disorder with no approved disease-modifying treatments. The biotechnology company has finalized a new, more stable formulation and an optimized dosing regimen designed to maximize the drug's therapeutic potential and overcome previous manufacturing challenges.

The decision to proceed with a 50mg dose, administered three times daily, follows a successful Phase 1 study and an intensive analysis of data from earlier trials. This move addresses a complex issue of drug variability that had previously clouded clinical results, renewing hope that neflamapimod could become a first-in-class therapy for a patient population in desperate need of new options.

Solving a Puzzle in Pharmaceutical Chemistry

CervoMed's journey to this point highlights a common but perilous challenge in drug development: polymorphism. This phenomenon occurs when a single drug substance can form different crystal structures, or polymorphs, each with unique properties like solubility and stability. An unstable form can convert into a more stable, but less soluble, version over time, drastically reducing how much of the drug is absorbed by the body—a measure known as bioavailability.

This exact issue impacted neflamapimod's Phase 2b RewinD-LB trial. An older batch of the drug, referred to as 'DP Batch A', was found to have degraded, delivering lower-than-intended plasma concentrations to patients. This underdosing led to inconclusive results in the trial's initial 16-week placebo-controlled portion. However, a newer, more stable batch, 'DP Batch B', used in the trial’s subsequent 32-week open-label extension, achieved the target drug levels and demonstrated significant clinical benefits.

"The selection of the dosage strength for our planned Phase 3 trial reflects more than a year of focused work by our Chemistry, Manufacturing and Controls team to understand and address the cross-batch variability and underperformance observed with the ineffective drug product batch," said John Alam, MD, Chief Executive Officer of CervoMed, in a statement.

Data from the RewinD-LB trial's extension phase showed that patients on the effective Batch B experienced a 52% lower decline on the Clinical Dementia Rating Sum of Boxes (CDR-SB) scale compared to those on Batch A. The effect was even more pronounced—an 82% lower decline—in the target patient group without co-existing Alzheimer's disease pathology. These clinical improvements were durable over 32 weeks and supported by positive changes in blood biomarkers of neurodegeneration, such as a significant reduction in plasma GFAP.

To prevent a recurrence of this issue, CervoMed developed a new, controlled manufacturing process. "The process historically used to manufacture neflamapimod produced drug substance containing multiple solid-state forms," explained Marco Verwijs, PhD, Executive Vice President of Technical Operations. "We have developed and implemented a controlled manufacturing process that only produces the stable crystal form of neflamapimod."

While this stable form is inherently less soluble, the company has compensated by increasing the dose from 40mg to 50mg. This adjustment is designed to precisely replicate the plasma drug concentrations that proved effective with Batch B, thereby de-risking the pivotal Phase 3 study and ensuring it is a true test of the drug's potential.

A Beacon of Hope for a Neglected Dementia

Dementia with Lewy Bodies is the second most common form of progressive dementia, affecting an estimated 600,000 people across the seven major global markets. The disease is characterized by a debilitating combination of cognitive decline, Parkinson's-like motor symptoms, fluctuating alertness, and distressing visual hallucinations. Patients and their families face a grim reality, as the current treatment landscape offers only symptomatic relief.

Standard treatments include acetylcholinesterase inhibitors like donepezil and rivastigmine, which are borrowed from the Alzheimer's playbook and offer modest cognitive benefits. However, no therapy exists to slow or halt the underlying disease progression driven by neuroinflammation and synaptic dysfunction. This therapeutic void has created a global market valued at over $6 billion in 2024, which is projected to grow as the population ages.

Neflamapimod works by targeting p38 MAP kinase, a key enzyme involved in both neuroinflammation and the breakdown of synapses—the connections between brain cells that are vital for memory and cognition. By inhibiting this enzyme, the drug aims to reverse synaptic dysfunction and protect neuron health. The promising results seen in patients without Alzheimer's co-pathology suggest neflamapimod may be particularly effective at targeting the specific disease mechanisms of pure DLB.

CervoMed's progress is a significant development in a field with a high rate of failure. The company has already secured Fast Track designation from the U.S. Food and Drug Administration (FDA) and has reached an agreement with the agency on the design of its registration trial.

The Path Forward: A Targeted Trial and a Financial Gauntlet

With the scientific and formulation challenges addressed, CervoMed is preparing for a single, global Phase 3 trial scheduled to begin in the second half of 2026. Based on FDA guidance, the study will enroll approximately 300 patients and will be randomized, double-blind, and placebo-controlled—the gold standard for clinical evidence.

A key feature of the trial design is its focus on a specific patient population. The study will exclusively enroll DLB patients who have no evidence of significant Alzheimer's disease co-pathology, as determined by brain imaging or cerebrospinal fluid analysis. This enrichment strategy is a direct lesson from the Phase 2b trial, which showed the greatest benefit in this subgroup. By targeting the patients most likely to respond, CervoMed aims to maximize the chances of a clear and positive outcome.

However, a significant hurdle remains: funding. The company's press release explicitly states that the trial's initiation is "subject to available funding." Running a global Phase 3 study is an expensive endeavor, often costing hundreds of millions of dollars.

According to its latest financial filings as of September 30, 2025, CervoMed had $27.3 million in cash, cash equivalents, and marketable securities. While the company has been adept at securing non-dilutive grant funding from the National Institute on Aging, its current cash reserves are projected to fund operations only into the third quarter of 2026. The company reported a net loss of $18.9 million for the first nine months of 2025, reflecting the high costs of late-stage clinical development.

Successfully financing the pivotal trial is now the company's most pressing challenge. Having solved the complex chemistry of neflamapimod, CervoMed must now convince investors that its refined drug and targeted trial design represent a compelling opportunity in the high-stakes world of neurodegenerative disease therapeutics.